A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of an Influenza A Vaccine (FP-01.1).

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of an Influenza A Vaccine (FP-01.1).

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs FP 01-Immune Targeting Systems (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Immune Targeting Systems
  • Most Recent Events

    • 13 Sep 2012 Actual patient number changed to 48 according to an Immune Targeting Systems media release.
    • 23 Mar 2012 Actual patient number added 49 according to ClinicalTrials.gov.
    • 23 Mar 2012 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top